Product Images Alendronate Sodium
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 8 images provide visual information about the product associated with Alendronate Sodium NDC 50090-3126 by A-s Medication Solutions, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
This is a table showing the increase in bone mineral density (BMD) in postmenopausal women with osteoporosis after three years of treatment with Alendronate 10 mg/day. The BMD increase is listed as a mean percentage increase relative to placebo and is shown for three different areas of the body: the lumbar spine, femoral neck, and trochanter. The table also includes reference numbers, but they are not readable due to errors.*
Description: This appears to be a graph from a study on Osteoporosis treatment in postmenopausal women. The graph compares the effect of alendronate 10mg/day versus a placebo on Lumbar Spine BMD Percent Change From Baseline over a period of 36 months. However, the information provided is limited and difficult to interpret without further context.*
This document presents the effect of Alendronate 40 mg/day on serum alkaline phosphatase in patients with Paget's Disease of Bone in comparison to Placebo or Etidronate 400 mg/day, based on multinational and U.S. studies. It includes a graph showing the mean % change from baseline over a period of 6 months.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.